Website: thermofisher.com
Customer Service (US): 1 800 955 6288 ext. 1
Technical Support (US): 1 800 955 6288 ext. 441
thermofisher.com/contactus

Performance guaranteed

ERCC1 Monoclonal Antibody (8F1)

Catalog Number MA5-13912

Product data sheet

Details	
Size	500 µL
Host/Isotope	Mouse / IgG2b
Class	Monoclonal
Type	Antibody
Clone	8F1
Immunogen	Recombinant full length human ERCC1 protein
Conjugate	Unconjugated
Form	Liquid
Concentration	0.2 mg/mL
Purification	Protein A
Storage buffer	PBS, pH 7.4, with 0.2% BSA
Contains	0.09% sodium azide
Storage Conditions	4° C

Species Reactivity	
Species reactivity	Human, Mouse, Rat
Published species	Hamster, Human, Not Applicable

Tested Applications	Dilution *
Flow Cytometry (Flow)	0.5-1 µg/test
Immunohistochemistry (Paraffin) (IHC (P))	1:100-1:500
Immunoprecipitation (IP)	Assay-dependent
Western Blot (WB)	Assay-dependent

Published Applications	
Immunohistochemistry (IHC)	See 58 publications below
Immunohistochemistry (Paraffin) (IHC (P))	See 2 publications below
Miscellaneous PubMed (Misc)	See 1 publications below
Western Blot (WB)	See 4 publications below
Immunocytochemistry (ICC/IF)	See 1 publications below
Immunoprecipitation (IP)	See 3 publications below

* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.

Product specific information

MA5-13912 targets ERCC1 in IP, IHC (P), FACS and WB applications and shows reactivity with human, mouse and rat samples. The MA5-13912 immunogen is recombinant full length human ERCC1 protein.

Background/Target Information

ERCC1 is a non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. It is responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). It participates in the processing of anaphase bridge-generating DNA structures, which consist in incompletely processed DNA lesions arising during S or G2 phase, and can result in cytokinesis failure. ERCC1 is also required for homology-directed repair (HDR) of DNA double-strand breaks, in conjunction with SLX4. (Uniprot)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product Images For ERCC1 Monoclonal Antibody (8F1)



ERCC1 Antibody (MA5-13912) in IHC (P)

Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human lung adenocarcinoma (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



ERCC1 Antibody (MA5-13912) in IHC (P)

Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Human tonsil tissue (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



ERCC1 Antibody (MA5-13912) in IHC (P)

Immunohistochemistry analysis of ERCC1 showing positive staining in the nucleus and cytoplasm of paraffin-treated Rat lymph node (right) compared with a negative control in the absence of primary antibody (left). To expose target proteins, antigen retrieval method was performed using 10mM sodium citrate (pH 6.0) microwaved for 8-15 min. Following antigen retrieval, tissues were blocked in 3% H2O2-methanol for 15 min at room temperature, washed with ddH2O and PBS, and then probed with a ERCC1 monoclonal antibody (Product # MA5-13912) diluted by 3% BSA-PBS at a dilution of 1:100 overnight at 4°C in a humidified chamber. Tissues were washed extensively PBST and detection was performed using an HRP-conjugated secondary antibody followed by colorimetric detection using a DAB kit. Tissues were counterstained with hematoxylin and dehydrated with ethanol and xylene to prep for mounting.



ERCC1 Antibody (MA5-13912) in WB

Western blot analysis of ERCC1 was performed by loading 25 µg of Hela cell lysates onto an SDS polyacrylamide gel. Proteins were transferred to a PVDF membrane and blocked at 4ºC overnight. The membrane was probed with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1:200 overnight at 4°C, washed in TBST, and probed with an HRP-conjugated secondary antibody for 1 hr at room temperature in the dark. Chemiluminescent detection was performed using Pierce ECL Plus Western Blotting Substrate (Product # 32132). Results show a band at ~39 kDa.

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus



Cell: HepG2

Concentration: 1µg/test (100µl)

Theory location: Cytoplasm/Nucleus

ERCC1 Antibody (MA5-13912) in Flow

Flow cytometry analysis of ERCC1 in HepG2 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.



Cell: Hela

Concentration: 1µg/test (100µl)

Theory location: Cytoplasm/Nucleus

ERCC1 Antibody (MA5-13912) in Flow

Flow cytometry analysis of ERCC1 in Hela cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 1 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.



Cell: 3T3

Concentration: 0.5µg/test (100µl)

Theory location: Cytoplasm/Nucleus

ERCC1 Antibody (MA5-13912) in Flow

Flow cytometry analysis of ERCC1 in NIH-3T3 cells (green) compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with an ERCC1 monoclonal antibody (Product # MA5-13912) at a dilution of 0.5 µg/test for 40 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated secondary antibody and re-suspended in PBS for FACS analysis.

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

PubMed References For ERCC1 Monoclonal Antibody (8F1)

58 Immunohistochemistry References

Species / Dilution	Summary
Human / 1:100	MA5-13912 was used in immunohistochemistry to study the association of low ERCC1 expression with poor survival in cervical cancer patients treated with radiation therapy Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2010; 97: 352) **"Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone."** Author(s):Doll CM,Prystajecky M,Eliasziw M,Klimowicz AC,Petrillo SK,Craighead PS,Hao D,Diaz R,Lees-Miller SP, Magliocco AM PubMed Article URL:http://dx.doi.org/10.1016/j.radonc.2010.08.019
Human / 1:100	MA5-13912 was used in immunohistochemistry to investigate the effect of specific markers for adrenocortical carcinoma prognosis after specific chemotherapy Endocrine-related cancer (2010; 17: 797) **"Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma."** Author(s):Malandrino P,Al Ghuzlan A,Castaing M,Young J,Caillou B,Travagli JP,Elias D,de Baere T,Dromain C,Paci A, Chanson P,Schlumberger M,Leboulleux S,Baudin E PubMed Article URL:http://dx.doi.org/10.1677/ERC-09-0341
Human / 1:100	MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of excision repair cross complementing group 1 in adrenocortical carcinoma patients Endocrine-related cancer (2009; 16: 907) **"Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy."** Author(s):Ronchi CL,Sbiera S,Kraus L,Wortmann S,Johanssen S,Adam P,Willenberg HS,Hahner S,Allolio B,Fassnacht M PubMed Article URL:http://dx.doi.org/10.1677/ERC-08-0224
Human / Not Cited	MA5-13912 was used in immunohistochemistry to study the prognostic value of ECCR1 and EGFR expression measured in non-small cel lung cancer fine-needle aspiration biopsies Revista portuguesa de pneumologia (2015; 20: 200) **"ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples."** Author(s):Kalogeraki A,Karvela-Kalogeraki I,Tamiolakis D,Petraki P,Saridaki Z,Tzardi M PubMed Article URL:http://dx.doi.org/10.1016/j.rppneu.2013.11.002
Human / 1:300	MA5-13912 was used in immunohistochemistry to study the roles of ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2010; 5: 453) **"ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival."** Author(s):Skov BG,Holm B,Erreboe A,Skov T,Mellemgaard A PubMed Article URL:http://dx.doi.org/10.1097/JTO.0b013e3181ca063b
Human / 1:200	MA5-13912 was used in immunohistochemistry to study the potential prognostic and predictive value of ERCC1 and BRCA1 immunohistochemical expression and polymorphisms in advanced non-small cell lung cancer British journal of cancer (2013; 108: 1695) **"ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin."** Author(s):Tiseo M,Bordi P,Bortesi B,Boni L,Boni C,Baldini E,Grossi F,Recchia F,Zanelli F,Fontanini G,Naldi N,Campanini N,Azzoni C,Bordi C,Ardizzoni A PubMed Article URL:http://dx.doi.org/10.1038/bjc.2013.127
Human / Not Cited	MA5-13912 was used in immunohistochemistry to study the prognostic value of EGFR mutations and ERCC1 expression in patients receiving platinum-based chemotherapy for non-small cell lung cancer PloS one (2014; 8:) **"Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy."** Author(s):Yamashita F,Azuma K,Yoshida T,Yamada K,Kawahara A,Hattori S,Takeoka H,Zaizen Y,Kawayama T,Kage M, Hoshino T PubMed Article URL:http://dx.doi.org/10.1371/journal.pone.0071356

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to investigate the prognostic significance of multiple genes for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Human / 1:25	Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (2011; 16: 74) **"Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy."** Author(s):Kim KH,Kwon HC,Oh SY,Kim SH,Lee S,Kwon KA,Jang JS,Kim MC,Kim SJ,Kim HJ PubMed Article URL:http://dx.doi.org/10.3109/1354750X.2010.533284
	MA5-13912 was used in immunohistochemistry to study whether personalized neoadjuvant chemotherapy is feasible in patients with early-stage rectal cancer
Human / 1:100	American journal of clinical oncology (2014; 37: 117) **"A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer."** Author(s):Cubillo A,Hernando-Requejo O,García-García E,Rodriguez-Pascual J,De Vicente E,Morelli P,Rubio C,López-Ríos F,Muro A,López U,Prados S,Quijano Y,Hidalgo M PubMed Article URL:http://dx.doi.org/10.1097/COC.0b013e31826e0703
	MA5-13912 was used in immunohistochemistry to evaluate excision repair cross-complementation group 1 ERCC1 as a biomarker for treatment of advanced non-small-cell lung cancer
Human / 1:200	Annals of oncology : official journal of the European Society for Medical Oncology (2010; 21: 1817) **"ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial."** Author(s):Vilmar AC,Santoni-Rugiu E,Sørensen JB PubMed Article URL:http://dx.doi.org/10.1093/annonc/mdq053
	MA5-13912 was used in immunohistochemistry to investigate the clinical significance of breast cancer resistance protein in small-cell lung cancer
Human / 1:100	Lung cancer (Amsterdam, Netherlands) (2009; 65: 105) **"Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer."** Author(s):Kim YH,Ishii G,Goto K,Ota S,Kubota K,Murata Y,Mishima M,Saijo N,Nishiwaki Y,Ochiai A PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2008.10.008
	MA5-13912 was used in immunohistochemistry to investigate the prognostic effectiveness of thymidylate synthase in the chemotherapy of malignant pleural mesothelioma
Human / 1:100	Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010; 28: 1534) **"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy."** Author(s):Righi L,Papotti MG,Ceppi P,Billè A,Bacillo E,Molinaro L,Ruffini E,Scagliotti GV,Selvaggi G PubMed Article URL:http://dx.doi.org/10.1200/JCO.2009.25.9275
	MA5-13912 was used in immunohistochemistry to characterize ERCC1 protein in squamous cell carcinomas of the head and neck and the effects of treatment
Human / Not Cited	Head & neck (2012; 34: 785) **"Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status."** Author(s):Hao D,Lau HY,Eliasziw M,Box A,Diaz R,Klimowicz AC,Shin B,Lees-Miller SP,Magliocco AM PubMed Article URL:http://dx.doi.org/10.1002/hed.21817
	MA5-13912 was used in immunohistochemistry to study the efficacy of combined cetuximab and modified FOLFOX6 treatment in a phase II gastric cancer trial
Human / 1:100	British journal of cancer (2009; 100: 298) **"Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer."** Author(s):Han SW,Oh DY,Im SA,Park SR,Lee KW,Song HS,Lee NS,Lee KH,Choi IS,Lee MH,Kim MA,Kim WH,Bang YJ,Kim TY PubMed Article URL:http://dx.doi.org/10.1038/sj.bjc.6604861
	MA5-13912 was used in immunohistochemistry to study ERCC1 expression in triple negative breast carcinoma
Human / 1:100	Breast cancer research and treatment (2008; 111: 569) **"ERCC1 expression in triple negative breast carcinoma: the paradox revisited."** Author(s):Sidoni A,Cartaginese F,Colozza M,Gori S,Crinó L PubMed Article URL:http://dx.doi.org/10.1007/s10549-007-9804-4

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

Human / 1:100	MA5-13912 was used in immunohistochemistry to study the value of ERCC1 expression in predicting chemoradiation resistance and poor outcome in oesophageal cancer European journal of cancer (Oxford, England : 1990) (2008; 44: 54) **"ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer."** Author(s):Kim MK,Cho KJ,Kwon GY,Park SI,Kim YH,Kim JH,Song HY,Shin JH,Jung HY,Lee GH,Choi KD,Kim SB PubMed Article URL:http://dx.doi.org/10.1016/j.ejca.2007.09.006
Human / Not Cited	MA5-13912 was used in immunohistochemistry to study adjuvant platinum/docetaxel chemotherapy with or without radiation in a phase III gastric cancer clinical trial Cancer chemotherapy and pharmacology (2010; 65: 1009) **"A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer."** Author(s):Bamias A,Karina M,Papakostas P,Kostopoulos I,Bobos M,Vourli G,Samantas E,Christodoulou Ch, Pentheroudakis G,Pectasides D,Dimopoulos MA,Fountzilas G PubMed Article URL:http://dx.doi.org/10.1007/s00280-010-1256-6
Human / 1:100	MA5-13912 was used in immunohistochemistry to perform a phase II clinical trial in patients with advanced metastatic colorectal cancer to study the feasibility of a targeted personalized chemotherapy approach American journal of clinical oncology (2016; 39: 236) **"Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer."** Author(s):Cubillo A,Rodriguez-Pascual J,López-Ríos F,Plaza C,García E,Álvarez R,de Vicente E,Quijano Y,Hernando O, Rubio C,Perea S,Sanchez G,Hidalgo M PubMed Article URL:http://dx.doi.org/10.1097/COC.0000000000000045
Human / 1:400	MA5-13912 was used in immunohistochemistry to investigate ERCC1, RPA and XPF expression in different types of smokers with lung adenocarcinoma Annals of oncology : official journal of the European Society for Medical Oncology (2009; 20: 1257) **"The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma."** Author(s):Planchard D,Domont J,Taranchon E,Monnet I,Tredaniel J,Caliandro R,Validire P,Besse B,Soria JC,Fouret P PubMed Article URL:http://dx.doi.org/10.1093/annonc/mdn785
Human / 1:300	MA5-13912 was used in immunohistochemistry to study ERCC1 protein expression as a predictor of platinum resistance in epithelial ovarian cancer International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2009; 19: 820) **"The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer."** Author(s):Steffensen KD,Waldstrøm M,Jakobsen A PubMed Article URL:http://dx.doi.org/10.1111/IGC.0b013e3181a12e09
Human / 1:100	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression levels in patients with uterine cervical adenocarcinoma International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2011; 21: 1479) **"The relationship between ERCC1 expression and clinical outcome in patients with FIGO stage I to stage II uterine cervical adenocarcinoma."** Author(s):Hasegawa K,Kato R,Torii Y,Ichikawa R,Oe S,Udagawa Y PubMed Article URL:http://dx.doi.org/10.1097/IGC.0b013e31822265e7
Human / 1:50	MA5-13912 was used in immunohistochemistry to study the predictive value of ERCC1 expression in locoregionally advanced nasopharyngeal carcinoma patients treated with cisplatin-based chemotherapy Oral oncology (2012; 48: 964) **"Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy."** Author(s):Huang PY,Li Y,Mai HQ,Luo RZ,Cai YC,Zhang L PubMed Article URL:http://dx.doi.org/10.1016/j.oraloncology.2012.04.003
Human / Not Cited	MA5-13912 was used in immunohistochemistry to study whether there is a correlation between DNA repair capacity following cisplatin therapy and the expression of different ECCR1 isoforms The New England journal of medicine (2013; 368: 1101) **"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer."** Author(s):Friboulet L,Olaussen KA,Pignon JP,Shepherd FA,Tsao MS,Graziano S,Kratzke R,Douillard JY,Seymour L, Pirker R,Filipits M,André F,Solary E,Ponsonnailles F,Robin A,Stoclin A,Dorvault N,Commo F,Adam J,Vanhecke E, Saulnier P,Thomale J,Le Chevalier T,Dunant A,Rousseau V,Le Teuff G,Brambilla E,Soria JC PubMed Article URL:http://dx.doi.org/10.1056/NEJMoa1214271

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to study the efficacy and feasibility of integrating pemetrexed in the therapy of patients with stage III non-small cell lung cancer
Human / 1:200	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2011; 6: 927) **"Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer."** Author(s):Gadgeel SM,Ruckdeschel JC,Patel BB,Wozniak A,Konski A,Valdivieso M,Hackstock D,Chen W,Belzer K,Burger AM,Marquette L,Turrisi A PubMed Article URL:http://dx.doi.org/10.1097/JTO.0b013e3182156109
	MA5-13912 was used in immunohistochemistry to study the value of ERCC1 expression in predicting response and survival in head and neck squamous cell carcinoma treated with cisplatin
Human / 1:300	Clinical cancer research : an official journal of the American Association for Cancer Research (2007; 13: 3855) **"Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma."** Author(s):Handra-Luca A,Hernandez J,Mountzios G,Taranchon E,Lacau-St-Guily J,Soria JC,Fouret P PubMed Article URL:http://dx.doi.org/10.1158/1078-0432.CCR-07-0252
	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 protein expression in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy
Human / 1:100	Lung cancer (Amsterdam, Netherlands) (2009; 65: 377) **"Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy."** Author(s):Lee HW,Choi YW,Han JH,Kim JH,Jung JH,Jeong SH,Kang SY,Choi JH,Oh YT,Park KJ,Hwang SC,Sheen SS PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2008.12.005
	MA5-13912 was used in immunohistochemistry to study ERCC1 as a predictive marker of the benefit of preoperative chemoradiotherapy in locally advanced esophageal cancers
Human / Not Cited	Clinical cancer research : an official journal of the American Association for Cancer Research (2008; 14: 4225) **"Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy."** Author(s):Kim MK,Cho KJ,Kwon GY,Park SI,Kim YH,Kim JH,Song HY,Shin JH,Jung HY,Lee GH,Choi KD,Kim SB PubMed Article URL:http://dx.doi.org/10.1158/1078-0432.CCR-07-4848
	MA5-13912 was used in immunohistochemistry to study the role of deficient expression of DNA repair enzymes in early progression to sporadic colon cancer
Human / 2 µg/mL	Genome integrity (2012; 3:) **"Deficient expression of DNA repair enzymes in early progression to sporadic colon cancer."** Author(s):Facista A,Nguyen H,Lewis C,Prasad AR,Ramsey L,Zaitlin B,Nfonsam V,Krouse RS,Bernstein H,Payne CM,Stern S,Oatman N,Banerjee B,Bernstein C PubMed Article URL:http://dx.doi.org/10.1186/2041-9414-3-3
	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1, hRad51, and BRCA1 protein expression in patients with stage III/IV non-small cell lung cancer
Human / 1:200	Lung cancer (Amsterdam, Netherlands) (2005; 50: 211) **"ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy."** Author(s):Wachters FM,Wong LS,Timens W,Kampinga HH,Groen HJ PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2005.06.013
	MA5-13912 was used in immunohistochemistry to study the role of ERCC1 in repairing DNA in non-small-cell lung cancer treated with cisplatin
Human / 1:300	The New England journal of medicine (2006; 355: 983) **"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy."** Author(s):Olaussen KA,Dunant A,Fouret P,Brambilla E,André F,Haddad V,Taranchon E,Filipits M,Pirker R,Popper HH,Stahel R,Sabatier L,Pignon JP,Tursz T,Le Chevalier T,Soria JC PubMed Article URL:http://dx.doi.org/10.1056/NEJMoa060570
	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression and clinicopathologigal parameters in Chinese patients with stage III/N2 non-small cell lung cancer
Human / 1:100	Journal of cardiothoracic surgery (2013; 8:) **"Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer."** Author(s):Yan D,Wei P,An G,Chen W PubMed Article URL:http://dx.doi.org/10.1186/1749-8090-8-149

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to study the outcomes of gefitinib treatment in head and neck cancer patients
Human / 1:50	Clinical cancer research : an official journal of the American Association for Cancer Research (2012; 18: 5123) **"Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02)."** Author(s):Thariat J,Bensadoun RJ,Etienne-Grimaldi MC,Grall D,Penault-Llorca F,Dassonville O,Bertucci F,Cayre A,De Raucourt D,Geoffrois L,Finetti P,Giraud P,Racadot S,Morinière S,Sudaka A,Van Obberghen-Schilling E,Milano G PubMed Article URL:http://dx.doi.org/10.1158/1078-0432.CCR-12-1518
	MA5-13912 was used in immunohistochemistry to study the predictive and prognostic value of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
Human / 1:50	Japanese journal of clinical oncology (2010; 40: 286) **"Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin."** Author(s):Shao YY,Kuo KT,Hu FC,Lu YS,Huang CS,Liau JY,Lee WC,Hsu C,Kuo WH,Chang KJ,Lin CH,Cheng AL PubMed Article URL:http://dx.doi.org/10.1093/jjco/hyp184
	MA5-13912 was used in immunohistochemistry to study the role of p38-MAPK in lung cancer cell viability in light and non-smoking patients
Human / 1:300	Cancer (2012; 118: 5015) **"p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients."** Author(s):Planchard D,Camara-Clayette V,Dorvault N,Soria JC,Fouret P PubMed Article URL:http://dx.doi.org/10.1002/cncr.27510
	MA5-13912 was used in immunohistochemistry to study biomarkers for predicting the response to capecitabine and cisplatin combination chemotherapy in metastatic oesophageal squamous cell cancer
Human / 1:200	British journal of cancer (2010; 103: 845) **"Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma."** Author(s):Lee S,Park YH,Kim KH,Cho EY,Ahn YC,Kim K,Shim YM,Ahn JS,Park K,Im YH PubMed Article URL:http://dx.doi.org/10.1038/sj.bjc.6605831
	MA5-13912 was used in immunohistochemistry to detect advanced lung cancer using the ERCC1 biomarker
Human / 1:200	European journal of cancer (Oxford, England : 1990) (2010; 46: 1554) **"ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial."** Author(s):Vilmar A,Santoni-Rugiu E,Sørensen JB PubMed Article URL:http://dx.doi.org/10.1016/j.ejca.2010.02.045
	MA5-13912 was used in immunohistochemistry to study the association between ERCC1 status and overall survival after chemotherapy for inoperable non-small cell lung cancer
Human / 1:300	Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009; 27: 4254) **"Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine."** Author(s):Holm B,Mellemgaard A,Skov T,Skov BG PubMed Article URL:http://dx.doi.org/10.1200/JCO.2008.18.8631
	MA5-13912 was used in immunohistochemistry to study the predictive value of measuring TRAP1 and ERCC1 in oxaliplatin plus 5-fluorouracil combination-treated metastatic colorectal cancer
Human / 1:400	Cancer research and treatment (2014; 46: 55) **"Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil."** Author(s):Han JJ,Baek SK,Lee JJ,Kim GY,Kim SY,Lee SH PubMed Article URL:http://dx.doi.org/10.4143/crt.2014.46.1.55
	MA5-13912 was used in immunohistochemistry to study the relationship between the response of testicular germ cell tumors to cisplatin therapy and ERCC1 and XPA polymorphisms and expression levels
Human / 1:300	British journal of cancer (2013; 109: 68) **"Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours."** Author(s):Mendoza J,Martínez J,Hernández C,Pérez-Montiel D,Castro C,Fabián-Morales E,Santibáñez M,González-Barrios R,Díaz-Chávez J,Andonegui MA,Reynoso N,Oñate LF,Jiménez MA,Núñez M,Dyer R,Herrera LA PubMed Article URL:http://dx.doi.org/10.1038/bjc.2013.303

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to study the predictive value of Topo2A protein expression in survival of locally advanced soft tissues sarcomas
Human / 1:400	European journal of cancer (Oxford, England : 1990) (2011; 47: 1319) **"Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas."** Author(s):Rodrigo RS,Nathalie A,Elodie T,Gonzalo GA,Philippe T,Françoise D,Julien D,Angela C,Bérénice B,Jean-Yves B, Jean-Michel C,Jean B,Sylvie B,Axel le C PubMed Article URL:http://dx.doi.org/10.1016/j.ejca.2011.02.010
	MA5-13912 was used in immunohistochemistry to compare the expression of diagnostic biomarkers in bronchial biopsies and surgical specimens of non-small-cell lung cancer
Human / 1:300	Annals of oncology : official journal of the European Society for Medical Oncology (2007; 18: 1043) **"Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer."** Author(s):Taillade L,Penault-Llorca F,Boulet T,Fouret P,Michiels S,Taranchon E,Mountzios G,Validire P,Domont J,Girard P,Grunenwald D,Le Chevalier T,Soria JC PubMed Article URL:http://dx.doi.org/10.1093/annonc/mdm072
	MA5-13912 was used in immunohistochemistry to investigate the relationship of ERCC1 expression with survival of ovarian cancer patients
Human / Not Cited	Gynecologic oncology (2010; 119: 325) **"Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma."** Author(s):Scheil-Bertram S,Tylus-Schaaf P,du Bois A,Harter P,Oppitz M,Ewald-Riegler N,Fisseler-Eckhoff A PubMed Article URL:http://dx.doi.org/10.1016/j.ygyno.2010.07.018
	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy
Human / 1:100	Lung cancer (Amsterdam, Netherlands) (2013; 82: 324) **"Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy."** Author(s):Vassalou H,Stathopoulos E,Fiolitaki G,Koutsopoulos A,Voutsina A,Georgoulias V,Mavroudis D PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2013.08.001
	MA5-13912 was used in immunohistochemistry to study the differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Human / 1:400	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2009; 4: 1212) **"Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites."** Author(s):Gomez-Roca C,Raynaud CM,Penault-Llorca F,Mercier O,Commo F,Morat L,Sabatier L,Dartevelle P,Taranchon E,Besse B,Validire P,Italiano A,Soria JC PubMed Article URL:http://dx.doi.org/10.1097/JTO.0b013e3181b44321
	MA5-13912 was used in immunohistochemistry to study the prognostic value of low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine
Human / 1:200	Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2012; 7: 249) **"Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival."** Author(s):Zimling ZG,Sørensen JB,Gerds TA,Bech C,Andersen CB,Santoni-Rugiu E PubMed Article URL:http://dx.doi.org/10.1097/JTO.0b013e318233d6a9
	MA5-13912 was used in immunohistochemistry to study the prognostic significance of Bax, ERCC1, and TS in advanced gastric cancer patients treated with FOLFOX palliative chemotherapy
Human / 1:100	Digestive diseases and sciences (2011; 56: 131) **"Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy."** Author(s):Jeong SH,Han JH,Kim JH,Ahn MS,Hwang YH,Lee HW,Kang SY,Park JS,Choi JH,Lee KJ,Sheen SS,Lim HY PubMed Article URL:http://dx.doi.org/10.1007/s10620-010-1280-8
	MA5-13912 was used in immunohistochemistry to study the predictive value of several biomarkers in patients undergoing treatment for locally advanced head and neck cancerr
Human / 1:450	Journal of oncology (2011; 2009:) **"MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer."** Author(s):Fountzilas G,Kalogera-Fountzila A,Lambaki S,Wirtz RM,Nikolaou A,Karayannopoulou G,Bobos M,Kotoula V, Murray S,Lambropoulos A,Aravantinos G,Markou K,Athanassiou E,Misailidou D,Kalogeras KT,Skarlos D PubMed Article URL:http://dx.doi.org/10.1155/2009/305908

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to study the predictive and prognostic value of ERCC1 expression in breast cancer
Human / Not Cited	Pathology, research and practice (2013; 209: 331) **"Clinicopathological significance of ERCC1 expression in breast cancer."** Author(s):Gerhard R,Carvalho A,Carneiro V,Bento RS,Uemura G,Gomes M,Albergaria A,Schmitt F PubMed Article URL:http://dx.doi.org/10.1016/j.prp.2013.02.009
Human / 1:1000	MA5-13912 was used in immunohistochemistry to determine if ERCC1 and Tau expression correlates with epithelial ovarian cancer outcome
	International journal of oncology (2014; 44: 1736) **"Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression."** Author(s):Steffensen KD,Smoter M,Waldstrøm M,Grala B,Bodnar L,Stec R,Szczylik C,Jakobsen A PubMed Article URL:http://dx.doi.org/10.3892/ijo.2014.2311
Human / 1:100	MA5-13912 was used in immunohistochemistry to study ERCC1 expression and tumor response to platinum-based chemotherapy in Chinese non-small cell lung cancer patients
	Medical oncology (Northwood, London, England) (2010; 27: 484) **"Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer."** Author(s):Wang X,Zhao J,Yang L,Mao L,An T,Bai H,Wang S,Liu X,Feng G,Wang J PubMed Article URL:http://dx.doi.org/10.1007/s12032-009-9239-3
Human / Not Cited	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 in non-small cell lung cancer patients treated with platinum-based chemotherapy
	Cancer science (2007; 98: 1336) **"Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy."** Author(s):Azuma K,Komohara Y,Sasada T,Terazaki Y,Ikeda J,Hoshino T,Itoh K,Yamada A,Aizawa H PubMed Article URL:http://dx.doi.org/10.1111/j.1349-7006.2007.00557.x
Human / 1:50	MA5-13912 was used in immunohistochemistry to study the molecular and clinical determinants of survival in pancreatic cancer patients treated with second-line chemotherapy
	Anticancer research (2010; 30: 4289) **"Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey."** Author(s):Mancuso A,Sacchetta S,Saletti PC,Tronconi C,Milesi L,Garassino M,Martelli O,Leone A,Zivi A,Cerbone L, Recine F,Sollami R,Labianca R,Cavalli F,Sternberg CN PubMed Article URL:http://www.ncbi.nlm.nih.gov/pubmed/21036754
Human / 1:100	MA5-13912 was used in immunohistochemistry to study ERCC1 expression and the response to cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
	Lung cancer (Amsterdam, Netherlands) (2008; 59: 377) **"ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer."** Author(s):Fujii T,Toyooka S,Ichimura K,Fujiwara Y,Hotta K,Soh J,Suehisa H,Kobayashi N,Aoe M,Yoshino T,Kiura K,Date H PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2007.08.025
Human / 1:100	MA5-13912 was used in immunohistochemistry to study whether hormone receptor expression is correlated with clinical outcome in advanaced lung cancer treated with chemotherapy
	Clinical lung cancer (2012; 13: 416) **"Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy."** Author(s):Monica V,Longo M,Felice B,Scagliotti GV,Papotti M,Novello S PubMed Article URL:http://dx.doi.org/10.1016/j.cllc.2012.03.006
Human / 1:750	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 and thymidylate synthase expression in malignant pleural mesothelioma
	Clinical lung cancer (2013; 14: 164) **"Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma."** Author(s):Kao SC,Lee K,Klebe S,Henderson D,McCaughan B,Vardy J,Clarke S,van Zandwijk N PubMed Article URL:http://dx.doi.org/10.1016/j.cllc.2012.09.003

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

	MA5-13912 was used in immunohistochemistry to study the predictive value of ERCC1 expression in pancreatic adenocarcinoma
Human / Not Cited	Annals of surgical oncology (2011; 18: 2699) **"Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection."** Author(s):Maithel SK,Coban I,Kneuertz PJ,Kooby DA,El-Rayes BF,Kauh JS,Sarmiento J,Staley CA,Volkan Adsay N PubMed Article URL:http://dx.doi.org/10.1245/s10434-011-1610-x
	MA5-13912 was used in immunohistochemistry to study the prognostic value of ERCC1 expression in small cell lung cancer
Human / 1:100	Lung cancer (Amsterdam, Netherlands) (2008; 59: 95) **"Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer."** Author(s):Lee HW,Han JH,Kim JH,Lee MH,Jeong SH,Kang SY,Choi JH,Oh YT,Park KJ,Hwang SC,Sheen SS,Lim HY PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2007.07.023
	MA5-13912 was used in immunohistochemistry to study the predictive value of Bcl-2 expression in locally advanced non-small cell lung cancer undergoing cisplatin therapy
Human / 1:100	Lung cancer (Amsterdam, Netherlands) (2010; 68: 288) **"Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy."** Author(s):Jeong SH,Jung JH,Han JH,Kim JH,Choi YW,Lee HW,Kang SY,Hwang YH,Ahn MS,Choi JH,Oh YT,Chun M,Kang S,Park KJ,Hwang SC,Sheen SS PubMed Article URL:http://dx.doi.org/10.1016/j.lungcan.2009.06.003

2 Immunohistochemistry (Paraffin) References

Species / Dilution	Summary
	MA5-13912 was used in immunohistochemistry - paraffin section to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression
Not Applicable / 1:600	BMC cancer (2016; 16:) **"Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models."** Author(s):Koussounadis A,Langdon SP,Um I,Kay C,Francis KE,Harrison DJ,Smith VA PubMed Article URL:http://dx.doi.org/10.1186/s12885-016-2212-6
	MA5-13912 was used in immunohistochemistry - paraffin section to discuss the use of excision repair cross-complementing rodent repair deficiency, complementation group 1 expression for selecting patients for platinum-based chemotherapy.
Human / 1:100	Anticancer research (2014; 34: 3707) **"Comparison of two ERCC1 antibodies as prognostic and predictive biomarkers for early non-small cell lung cancer."** Author(s):Muley TR,Sianidou M,Thomas M,Bischoff H,Dienemann H,Meister M,Schneider MA,Schnabel PA,Warth A PubMed Article URL:http://www.ncbi.nlm.nih.gov/pubmed/24982391

1 Miscellaneous PubMed References

Species / Dilution	Summary
	MA5-13912 was used in immunohistochemistry - paraffin section to assess the association between nedaplatin sensitivity and the expression of biological factors relevant to cervical cancer
Human / 1:100	Oncology letters (2015; 10: 3591) **"Factors affecting platinum sensitivity in cervical cancer."** Author(s):Kato R,Hasegawa K,Torii Y,Udagawa Y,Fukasawa I PubMed Article URL:http://dx.doi.org/10.3892/ol.2015.3755

4 Western Blot References

Species / Dilution	Summary
	MA5-13912 was used in western blot to study the effect of conserved nuclease domain mutations of XPF on DNA reair and TRF2-mediated shortening of telomeres
Human / Not Cited	DNA repair (2007; 6: 157) **"XPF with mutations in its conserved nuclease domain is defective in DNA repair but functions in TRF2-mediated telomere shortening."** Author(s):Wu Y,Zacal NJ,Rainbow AJ,Zhu XD PubMed Article URL:http://dx.doi.org/10.1016/j.dnarep.2006.09.005

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus

Hamster / 1:200	MA5-13912 was used in western blot to investigate the role of ERCC1/XPF endonuclease in DNA repair in Chinese hamster cell line UV4 Nucleic acids research (2008; 36: 1) **"The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells."** Author(s):Al-Minawi AZ,Saleh-Gohari N,Helleday T PubMed Article URL:http://dx.doi.org/10.1093/nar/gkm888
Human / 1:200	MA5-13912 was used in western blot to investigate the molecular mechanisms of spontaneous mesenchymal stem cell transformation PloS one (2008; 3:) **"Molecular characterization of spontaneous mesenchymal stem cell transformation."** Author(s):Rubio D,Garcia S,Paz MF,De la Cueva T,Lopez-Fernandez LA,Lloyd AC,Garcia-Castro J,Bernad A PubMed Article URL:http://dx.doi.org/10.1371/journal.pone.0001398
Human / Not Cited	MA5-13912 was used in western blot to study the role of UHRF1 to DNA lesions. Cell reports (2015; 10: 1957) **"UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold."** Author(s):Tian Y,Paramasivam M,Ghosal G,Chen D,Shen X,Huang Y,Akhter S,Legerski R,Chen J,Seidman MM,Qin J,Li L PubMed Article URL:http://dx.doi.org/10.1016/j.celrep.2015.03.038

1 Immunocytochemistry References

Species / Dilution	Summary
Human / 1:100	MA5-13912 was used in immunocytochemistry, immunohistochemistry, and western blot to study the prognostic value of ERRC1 in p16-negative squamous cell head and neck cancers Clinical cancer research : an official journal of the American Association for Cancer Research (2013; 19: 6633) **"Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers."** Author(s):Mehra R,Zhu F,Yang DH,Cai KQ,Weaver J,Singh MK,Nikonova AS,Golemis EA,Flieder DB,Cooper HS,Lango M,Ridge JA,Burtness B PubMed Article URL:http://dx.doi.org/10.1158/1078-0432.CCR-13-0152

3 Immunoprecipitation References

Species / Dilution	Summary
Human / Not Cited	MA5-13912 was used in immunoprecipitation and western blot to study a novel Fanconi anemia subtype in which SLX4 is mutated Nature genetics (2011; 43: 138) **"SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype."** Author(s):Stoepker C,Hain K,Schuster B,Hilhorst-Hofstee Y,Rooimans MA,Steltenpool J,Oostra AB,Eirich K,Korthof ET,Nieuwint AW,Jaspers NG,Bettecken T,Joenje H,Schindler D,Rouse J,de Winter JP PubMed Article URL:http://dx.doi.org/10.1038/ng.751
Human / Not Cited	MA5-13912 was used in immunoprecipitation to study the distinct mechanisms by which XPF-ERCC1 regulates TRF2 function and maintenance of telomere length Mechanisms of ageing and development (2008; 129: 602) **"Human XPF controls TRF2 and telomere length maintenance through distinctive mechanisms."** Author(s):Wu Y,Mitchell TR,Zhu XD PubMed Article URL:http://dx.doi.org/10.1016/j.mad.2008.08.004
Human / Not Cited	MA5-13912 was used in immunoprecipitation to study SLX4 mutations in two patients with Fanconi anemia Nature genetics (2011; 43: 142) **"Mutations of the SLX4 gene in Fanconi anemia."** Author(s):Kim Y,Lach FP,Desetty R,Hanenberg H,Auerbach AD,Smogorzewska A PubMed Article URL:http://dx.doi.org/10.1038/ng.750

Thermo Fisher Scientific
3747 N. Meridian Road
Rockford, IL 61105 USA

thermofisher.com/contactus